Immunotherapeutic interventions of Triple Negative Breast Cancer

Triple Negative Breast Cancer (TNBC) is a highly heterogeneous subtype of breast cancer that lacks the expression of oestrogen receptors, progesterone receptors and human epidermal growth factor receptor 2. Although TNBC is sensitive to chemotherapy, the overall outcomes of TNBC are worse than for other breast cancers, and TNBC is still one of the most fatal diseases for women. With the discovery of antigens specifically expressed in TNBC cells and the developing technology of monoclonal antibodies, chimeric antigen receptors and cancer vaccines, immunotherapy is emerging as a novel promising option for TNBC. This review is mainly focused on the tumour microenvironment and host immunity, Triple Negative Breast Cancer and the clinical treatment of TNBC, novel therapies for cancer and immunotherapy for TNBC, and the future outlook for the treatment for TNBC and the interplay between the therapies, including immune checkpoint inhibitors, combination of immune checkpoint inhibitors with targeted treatments in TNBC, adoptive cell therapy, cancer vaccines. The review also highlights recent reports on the synergistic effects of immunotherapy and chemotherapy, antibody–drug conjugates, and exosomes, as potential multifunctional therapeutic agents in TNBC.

• Publication year

  2018

• Venue

  Journal of Translational Medicine

• Publication date

  2018-05-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/s12967-018-1514-7PMID 29848327PMCID 5977468
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY

  2019cited by this paper
• In‐vitro effect of pembrolizumab on different T regulatory cell subsets

  2018cited by this paper
• PLAC1-specific TCR-engineered T cells mediate antigen-specific antitumor effects in breast cancer.

  2018influential reference
• Checkpoint inhibitors in triple‐negative breast cancer (TNBC): Where to go from here

  2018cited by this paper
• Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC.

  2018cited by this paper
• Enhanced clinical-scale manufacturing of TCR transduced T-cells using closed culture system modules

  2018cited by this paper
• Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.

  2018cited by this paper
• TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer.

  2018cited by this paper
• IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor

  2018cited by this paper
• PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer

  2018cited by this paper
• Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer.

  2018cited by this paper
• Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1.

  2018cited by this paper
• CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells.

  2018cited by this paper
• Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

  2017cited by this paper
• Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development.

  2017influential reference
• Abstract S1-07: Immune sculpting of the triple negative breast cancer genome

  2017cited by this paper
• A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions

  2017cited by this paper
• Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC

  2017cited by this paper
• Abstract A37: Development and future of CAR T cell therapy for pancreatic ductal adenocarcinoma and triple negative breast cancer

  2017cited by this paper
• 50PDistinct immune microenvironments stratify triple-negative breast cancer and predict outcome

  2017cited by this paper
• Abstract P1-07-06: Immune signatures define and affect prognosis in triple-negative breast cancer subtypes

  2017cited by this paper
• Abstract P2-04-27: CTLA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer

  2017cited by this paper
• Bi-directional exosome-driven intercommunication between the hepatic niche and cancer cells

  2017cited by this paper
• PD-1/PD-L1 Pathway in Breast Cancer

  2017cited by this paper
• T-cell receptor-engineered T cells for cancer treatment: current status and future directions

  2017cited by this paper
• Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer

  2017cited by this paper
• Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer.

  2017cited by this paper
• PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?

  2017cited by this paper
• Tumor-derived IL-18 induces PD-1 expression on immunosuppressive NK cells in triple-negative breast cancer

  2017cited by this paper
• Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy

  2017cited by this paper
• Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours

  2017cited by this paper
• PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression

  2017cited by this paper
• Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance

  2017cited by this paper
• Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer

  2017cited by this paper
• Extracellular vesicles: An overview of biogenesis, function, and role in breast cancer

  2017cited by this paper
• Role for extracellular vesicles in the tumour microenvironment

  2017cited by this paper
• Identification of highly selective MMP‐14 inhibitory Fabs by deep sequencing

  2017influential reference
• Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.

  2017cited by this paper
• A novel immunotherapy targeting MMP-14 limits hypoxia, immune suppression and metastasis in triple-negative breast cancer models

  2017cited by this paper
• Exosome: emerging biomarker in breast cancer

  2017cited by this paper
• Synthetic Lethality Exploitation by an Anti–Trop-2-SN-38 Antibody–Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2–wild-type Triple-Negative Breast Cancer

  2017cited by this paper
• Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level

  2016cited by this paper
• Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma.

  2016cited by this paper
• Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first‐line therapy for triple‐negative, metastatic, or locally advanced breast cancer: Results from the GINECO A‐TaXel phase 2 study

  2016cited by this paper
• Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.

  2016cited by this paper
• Mesothelin Immunotherapy for Cancer: Ready for Prime Time?

  2016cited by this paper
• PD-L1 Expression Is Associated with Tumor FOXP3+ Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient

  2016cited by this paper
• Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer

  2016cited by this paper
• Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer

  2016cited by this paper
• Development of a specific affinity-matured exosite inhibitor to MT1-MMP that efficiently inhibits tumor cell invasion in vitro and metastasis in vivo

  2016cited by this paper
• EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape.

  2016influential reference
• Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review.

  2016cited by this paper
• Novel immunotherapy in the treatment of advanced non-small cell lung cancer

  2016cited by this paper
• Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

  2016cited by this paper
• Amphiregulin Confers Regulatory T Cell Suppressive Function and Tumor Invasion via the EGFR/GSK-3β/Foxp3 Axis*

  2016cited by this paper
• Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer.

  2016cited by this paper
• Abstract P4-04-06: Immune balance between tumor-infiltrating lymphocytes and tumor-associated macrophages impacts the outcome of triple negative breast cancer patients

  2016cited by this paper
• Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers

  2016cited by this paper
• Abstract 4977: Immunogenic chemotherapy synergize PD-1 blockade by enhancing dendritic cells infiltration in triple-negative breast cancer (TNBC)

  2016cited by this paper
• Regulatory T cells in cancer immunotherapy

  2016cited by this paper
• Abstract 4149: Direct immune cell contact to basal-like triple negative breast cancer cells evokes downregulation of EGFR and PD-L1

  2016cited by this paper
• Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.

  2016cited by this paper
• Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis

  2016cited by this paper
• Safety and initial clinical efficacy of a dendritic cell (DC) vaccine in locally advanced, triple-negative breast cancer (TNBC) patients (pts).

  2016cited by this paper
• The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis.

  2016cited by this paper
• Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting

  2016cited by this paper
• N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy.

  2016cited by this paper
• Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer

  2016cited by this paper
• Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer.

  2016cited by this paper
• Dendritic cells-based vaccine to inhibit triple-negative breast cancer cells proliferation.

  2016cited by this paper
• Brachyury, a vaccine target, is overexpressed in triple-negative breast cancer.

  2016cited by this paper
• A Real‐World Multicentre Retrospective Study of Paclitaxel‐Bevacizumab and Maintenance Therapy as First‐Line for HER2‐Negative Metastatic Breast Cancer

  2016cited by this paper
• Moving targets: Emerging roles for MMPs in cancer progression and metastasis.

  2015cited by this paper
• Permissive expansion and homing of adoptively transferred T cells in tumor‐bearing hosts

  2015cited by this paper
• Targeting ECM Disrupts Cancer Progression

  2015cited by this paper
• VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors

  2015cited by this paper
• NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma

  2015cited by this paper
• Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease.

  2015cited by this paper
• Blockade of MMP14 activity in murine breast carcinomas: implications for macrophages, vessels, and radiotherapy.

  2015cited by this paper
• Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer

  2015cited by this paper
• Expression of NY-ESO-1 in Triple-Negative Breast Cancer Is Associated with Tumor-Infiltrating Lymphocytes and a Good Prognosis

  2015influential reference
• Exosomes in development, metastasis and drug resistance of breast cancer

  2015cited by this paper
• Subtyping of triple‐negative breast cancer: Implications for therapy

  2015cited by this paper
• Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system.

  2015cited by this paper
• Role of inflammatory infiltrates in triple negative breast cancer

  2015cited by this paper
• Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.

  2015influential reference
• Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?

  2015cited by this paper
• Epidermal Growth Factor Receptor Expression in Triple Negative and Nontriple Negative Breast Carcinomas

  2015cited by this paper
• Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45)

  2015cited by this paper
• Mechanisms of tumor-induced T cell immune suppression and therapeutics to counter those effects

  2015cited by this paper
• Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.

  2015cited by this paper
• Abstract 2349: EGFR is transferred from triple negative breast cancer cells to immune cells via trogocytosis and expression of EGFR on immune cells is associated with high tumor grade of triple negative breast cancer patients

  2015cited by this paper
• Redefining the Breast Cancer Exosome Proteome by Tandem Mass Tag Quantitative Proteomics and Multivariate Cluster Analysis.

  2015cited by this paper
• Adoptive cell transfer as personalized immunotherapy for human cancer

  2015cited by this paper
• EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.

  2015cited by this paper
• PD-L1 Expression in Triple-Negative Breast Cancer

  2014cited by this paper
• BRCA1 Pathway Function in Basal-Like Breast Cancer Cells

  2014cited by this paper
• 261: Cancer-associated fibroblast (CAF)-derived exosome may mediate breast cancer progression by reducing exosomal microRNAs

  2014cited by this paper
• Novel antigens in non-small cell lung cancer: SP17, AKAP4, and PTTG1 are potential immunotherapeutic targets

  2014influential reference
• Digging a little deeper: the stages of invadopodium formation and maturation.

  2014cited by this paper

• Immunotherapy in Triple-Negative Breast Cancer: From Molecular Mechanisms to Precision Medicine-Overcoming Resistance and Optimizing Clinical Outcomes.

  2026cites this paper
• Isothermal nucleic acid amplification-based magnetic aptasensor for sensitive detection and in situ imaging of Trop-2 in triple-negative breast cancer.

  2025cites this paper
• Genetically Engineered Light‐Responsive In Situ Hydrogels for Immunomodulation and Multimodal Therapy in Metastatic Triple‐Negative Breast Cancer

  2025cites this paper
• Efferocytosis-related signatures identified via Single-cell analysis and machine learning predict TNBC outcomes and immunotherapy response

  2025cites this paper
• TMB as a predictive biomarker for ICI response in TNBC: current evidence and future directions for augmented anti-tumor responses

  2025cites this paper
• Biocompatible semiconducting molybdenum diselenide nanosheets with glycyrrhizic acid for enhanced photothermal cancer therapy.

  2025cites this paper
• Targeting Triple‐Negative Breast Cancer: Resistance Mechanisms and Therapeutic Advancements

  2025cites this paper
• Machine learning and single-cell analysis uncover distinctive characteristics of CD300LG within the TNBC immune microenvironment: experimental validation

  2025cites this paper
• Unleashing the Therapeutic Power of Natural Alkaloids in Triple‐Negative Breast Cancer: State‐of‐the‐Art Advances and Future Directions

  2025cites this paper
• Radiation-Based Multi-Modal Therapy Combining with Immunotherapy to Develop a Vaccine-Like Effective Treatment for Triple-Negative Breast Cancer

  2025cites this paper
• The involvement and application potential of exosomes in breast cancer immunotherapy

  2024cites this paper
• Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies.

  2024cites this paper
• Single-cell allelic transcriptomic analysis unravels intratumoral gene expression heterogeneity linked to TNBC pathogenesis

  2024cites this paper
• Biomaterials’ enhancement of immunotherapy for breast cancer by targeting functional cells in the tumor micro-environment

  2024cites this paper
• Integrating immunotherapy with conventional treatment regime for breast cancer patients- an amalgamation of armamentarium

  2024cites this paper
• Construction of Light and Temperature-Responsive Acrylamide Copolymer-Metal Organic Frameworks for Breast Cancer Therapy

  2024cites this paper
• Therapeutic effects of DOX-loaded hydrogel MOF nanocarriers on triple negative breast cancer and derivative design via reinforcement learning

  2024cites this paper
• Targeted photothermal cancer therapy using surface-modified transition metal dichalcogenides

  2024cites this paper
• NEDD9 is transcriptionally regulated by HDAC4 and promotes breast cancer metastasis and macrophage M2 polarization via the FAK/NF-κB signaling pathway

  2024cites this paper
• A Circadian Rhythm-related Signature to Predict Prognosis, Immunei Infiltration, and Drug Response in Breast Cancer.

  2024cites this paper
• Recent Advances in Immunotherapy for Breast Cancer: A Review

  2024cites this paper
• Remodeling of tumour microenvironment: strategies to overcome therapeutic resistance and innovate immunoengineering in triple-negative breast cancer

  2024cites this paper
• Immunotherapy in Combination with Chemotherapy for Triple-Negative Breast Cancer.

  2023cites this paper
• Emerging Futuristic Targeted Therapeutics

  2023cites this paper
• PCMT1 knockdown attenuates malignant properties by globally regulating transcriptome profiles in triple-negative breast cancer cells

  2023cites this paper
• Neoadjuvant Immunotherapy in Early, Triple-Negative Breast Cancers: Catching Up with the Rest

  2023cites this paper
• Current Advancements and Future Perspectives of Immunotherapy in Breast Cancer Treatment

  2023cites this paper
• Oncolytic therapy with recombinant vaccinia viruses targeting the interleukin-15 pathway elicits a synergistic response

  2023cites this paper
• Comparison of the oncolytic activity of recombinant vaccinia virus strains LIVP-RFP and MVA-RFP against solid tumors

  2023cites this paper
• Current Therapeutic Approaches and Promising Perspectives of Using Bioengineered Peptides in Fighting Chemoresistance in Triple-Negative Breast Cancer.

  2023cites this paper
• Prognostic Value of Tumor Infiltrating-Lymphocytes and EGFR Protein Expression of Tumor Cell in Patients with Triple-Negative Breast Cancer

  2022cites this paper
• Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer

  2022cites this paper
• Contracting triple-negative breast cancer with immunotherapeutic armamentarium: recent advances and clinical prospects

  2022cites this paper
• Predictive value of PD-L1 expression to the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer: A systematic review and meta-analysis

  2022cites this paper
• CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil

  2022cites this paper
• Role of Immunotherapy in the Treatment of Triple-Negative Breast Cancer: A Literature Review

  2022cites this paper
• Transcriptomic Profiling of Breast Cancer Cells Induced by Tumor-Associated Macrophages Generates a Robust Prognostic Gene Signature

  2022cites this paper
• Modern breast cancer therapy: from tamoxifen to T-cell engineering

  2022cites this paper
• Cellular and molecular basis of therapeutic approaches to breast cancer.

  2022cites this paper
• Zinc transporter LIV1: A promising cell surface target for triple negative breast cancer

  2022cites this paper
• Active nanomaterials containing YAPTAZ reshape tumor immune microenvironment and enhance sensitivity of triple-negative breast cancer to immunotherapy

  2022cites this paper
• Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice

  2022influential citation
• Tumor Microenvironment Characterization in Breast Cancer and an Immune Cell Infiltration Score Development, Validation, and Application

  2022cites this paper
• Potential of chimeric antigen receptor (CAR)‐redirected immune cells in breast cancer therapies: Recent advances

  2022cites this paper
• Assessment of CAR-T Cell-Mediated Cytotoxicity in 3D Microfluidic Cancer Co-Culture Models for Combination Therapy

  2022cites this paper
• New insights into the discovery of drugs for triple-negative breast cancer metastasis

  2022cites this paper
• Discovering the Triad between Nav1.5, Breast Cancer, and the Immune System: A Fundamental Review and Future Perspectives

  2022cites this paper
• Platinum is essential in neoadjuvant treatment of triple-negative breast cancer: a network meta-analysis

  2022cites this paper
• Research progress on immunotherapy in triple-negative breast cancer (Review)

  2022cites this paper
• Applications of Extracellular Vesicles in Triple-Negative Breast Cancer

  2022cites this paper
• Prospects of Immunotherapy for Triple-Negative Breast Cancer

  2022influential citation
• The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer

  2022cites this paper
• New Achievements for the Treatment of Triple-Negative Breast Cancer

  2022cites this paper
• New Approaches to Dendritic Cell-Based Therapeutic Vaccines Against HIV-1 Infection

  2022cites this paper
• Immunopharmacogenomics: a hope in the treatment of carcinoma

  2022cites this paper
• Assessment of CAR-T mediated and targeted cytotoxicity in 3D microfluidic TBNC co-culture models for combination therapy

  2021cites this paper
• The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.

  2021cites this paper
• Doxorubicin Hydrochloride-Loaded Nonionic Surfactant Vesicles to Treat Metastatic and Non-Metastatic Breast Cancer

  2021cites this paper
• Exosomes: powerful weapon for cancer nano-immunoengineering.

  2021cites this paper
• Therapeutic Advances in Oncology

  2021cites this paper
• Atlas of breast cancer infiltrated B-lymphocytes revealed by paired single-cell RNA-sequencing and antigen receptor profiling

  2021cites this paper
• Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition

  2021cites this paper
• Surface Expression of Kynurenine 3-Monooxygenase Promotes Proliferation and Metastasis in Triple-Negative Breast Cancers

  2021cites this paper
• A Novel Thienopyrimidine Analog, TPH104, Mediates Immunogenic Cell Death in Triple-Negative Breast Cancer Cells

  2021cites this paper
• Current research on circular RNAs and their potential clinical implications in breast cancer

  2021cites this paper
• Recent Progress on Immunotherapy for Breast Cancer: Tumor Microenvironment, Nanotechnology and More

  2021cites this paper
• Breast cancer immunotherapy: Current and novel approaches.

  2021cites this paper
• Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer

  2021cites this paper
• Group 2 innate lymphoid cells promote TNBC lung metastasis via the IL-13-MDSC axis in a murine tumor model.

  2021cites this paper
• Detachable Liposomes Combined Immunochemotherapy for Enhanced Triple-Negative Breast Cancer Treatment through Reprogramming of Tumor-Associated Macrophages.

  2021cites this paper
• Immunotherapy Treatment for Triple Negative Breast Cancer

  2021cites this paper
• Evolution of the Tumor Microenvironment toward Immune-Suppressive Seclusion during Brain Metastasis of Breast Cancer: Implications for Targeted Therapy

  2021cites this paper
• The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis

  2021cites this paper
• Immune Effect of Active Components of Traditional Chinese Medicine on Triple-Negative Breast Cancer

  2021cites this paper
• Therapeutic potential of CAR T cell in malignancies: A scoping review.

  2021cites this paper
• Triple-negative breast cancer: new treatment strategies in the era of precision medicine

  2020cites this paper
• Progress on Immunotherapy in Triple-Negative Breast Cancer

  2020cites this paper
• Folate-targeted PTEN/AKT/P53 signaling pathway promotes apoptosis in breast cancer cells

  2020cites this paper
• Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer

  2020influential citation
• Bispecific Antibodies for Triple Negative Breast Cancer.

  2020cites this paper
• Role of COX-2 inhibitors as maintenance therapy in non-metastatic triple negative breast cancer Egyptian patients, single institution study

  2020cites this paper
• Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer.

  2020cites this paper
• Vorinostat-loaded titanium oxide nanoparticles (anatase) induce G2/M cell cycle arrest in breast cancer cells via PALB2 upregulation

  2020cites this paper
• PD-1/PD-L1 axis importance and tumor microenvironment immune cells.

  2020cites this paper
• Identification of SCARA5 Gene as a Potential Immune-Related Biomarker for Triple-Negative Breast Cancer by Integrated Analysis

  2020cites this paper
• Anticancer Activity of Tetrandrine by Inducing Apoptosis in Human Breast Cancer Cell Line MDA-MB-231 In Vivo

  2020cites this paper
• Toll-like receptor (TLR) gene expression and immunostimulatory effect of CpG oligonucleotides in hormone receptor positive cell line T47D and triple negative breast cancer cell line MDA-MB-468

  2020cites this paper
• Tumor cell lysate-loaded immunostimulatory spherical nucleic acids as therapeutics for triple-negative breast cancer

  2020cites this paper
• Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide

  2020cites this paper
• Loss of the proprotein convertase Furin in T cells represses mammary tumorigenesis in oncogene-driven triple negative breast cancer.

  2020cites this paper
• EGFR‐targeted CAR‐T cells are potent and specific in suppressing triple‐negative breast cancer both in vitro and in vivo

  2020cites this paper
• Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer

  2020cites this paper
• microRNAs in the Antitumor Immune Response and in Bone Metastasis of Breast Cancer: From Biological Mechanisms to Therapeutics

  2020cites this paper
• FDG uptake reflects breast cancer immunological features: the PD-L1 expression and degree of TILs in primary breast cancer

  2020cites this paper
• The Missing Lnc: The Potential of Targeting Triple-Negative Breast Cancer and Cancer Stem Cells by Inhibiting Long Non-Coding RNAs

  2020cites this paper
• Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer

  2020cites this paper
• IMMUNEPOTENT CRP plus doxorubicin/cyclophosphamide chemotherapy remodel the tumor microenvironment in an air pouch triple-negative breast cancer murine model.

  2020cites this paper
• Saccharide analog, 2‐deoxy‐d‐glucose enhances 4‐1BB‐mediated antitumor immunity via PD‐L1 deglycosylation

  2020cites this paper
• Predictive value of exosomes and their cargo in drug response/resistance of breast cancer patients

  2020cites this paper
• Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study

  2020cites this paper